Scott A. Waldman, M.D., Ph.D. (Chairman )

Dr. Waldman is the Samuel M.V. Hamilton Professor of Medicine and Professor of Biochemistry and Molecular Pharmacology, and the Director of the Division of Clinical Pharmacology at Thomas Jefferson University . Also, he is the Director of the Developmental Therapeutics Program in the Kimmel Cancer Center at TJU. He is a past President of the American Society for Clinical Pharmacology and Therapeutics, and Regent of the American College of Clinical Pharmacology, and the Secretary-Treasurer of the American Board of Clinical Pharmacology. Dr. Waldman is the author of the patents that have been licensed to the Company under the TJU License Agreement. Dr. Waldman graduated with a B.S. in Anatomy from the State University of New York at Albany in 1975. He received his Ph.D. in Human Anatomy and Biochemistry from TJU in 1980 and his M.D. from Stanford University School of Medicine in 1987. Dr. Waldman is a founder of TDT and is the Senior Science Advisor and the Principal Investigator under the TJU Research Funding Agreement and the Principal Investigator under the two NCI-NIH grants for TDT’s lymph node and blood tests.